diclofenac has been researched along with Acute Edematous Pancreatitis in 63 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "High-dose rectal diclofenac suppository and epinephrine spray on duodenal papilla during endoscopic retrograde cholangiopancreatography (ERCP) may reduce the incidence of post-ERCP pancreatitis." | 9.41 | Randomized trial of high-dose rectal diclofenac suppository and epinephrine spray on duodenal papilla for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. ( Ashraf, A; Dar, HA; Javid, G; Khan, MA; Mohammad, S; Shah, A; Sheikh, NA; Singh, B, 2021) |
| "Both diclofenac and tramadol are equally effective in controlling pain in AP with similar safety profile." | 9.34 | Comparison of efficacy of diclofenac and tramadol in relieving pain in patients of acute pancreatitis: A randomized parallel group double blind active controlled pilot study. ( Dhaka, N; Gupta, V; Kochhar, R; Kumar, NS; Muktesh, G; Samanta, J; Samra, T; Sarma, P; Sinha, SK; Yadav, TD, 2020) |
| "We aimed to compare the efficacy of prophylactic, parenterally administered ceftazidime and rectally applied diclofenac sodium for the prophylaxis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP)." | 9.24 | Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial. ( Blažević, I; Bulić, Z; Giljača, V; Hauser, G; Poropat, G; Salkić, N; Štimac, D, 2017) |
| "Prophylaxis with diclofenac given rectally or intramuscularly is an effective option for the management of post-ERCP pancreatitis." | 9.22 | Rectal or intramuscular diclofenac reduces the incidence of pancreatitis afterendoscopic retrograde cholangiopancreatography. ( Ataseven, H; Biyik, M; Çifçi, S; Demir, A; Polat, İ; Uçar, E; Uçar, R, 2016) |
| "We aimed to investigate the preventive effect of oral diclofenac on pancreatitis after ERCP in a multicenter, randomized, prospective, placebo-controlled, double-blind trial." | 9.22 | No Benefit of Oral Diclofenac on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. ( Doi, S; Hayashi, T; Hisai, H; Ishiwatari, H; Iwashita, T; Kato, J; Kawakami, H; Kawakubo, K; Matsusaki, S; Ono, M; Sakamoto, N; Sonoda, T; Urata, T; Yasuda, I, 2016) |
| "Combination therapy with udenafil and aceclofenac is not effective for the prevention of post-ERCP pancreatitis." | 9.20 | Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter study. ( Cheon, YK; Choi, JS; Do, JH; Lee, TY; Oh, HC; Song, TJ, 2015) |
| "To assess the efficacy of intramuscular diclofenac and fluid replacement for prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis." | 9.14 | Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis. ( Demirkan, H; Saritas, U; Senol, A, 2009) |
| "This trial shows that rectal diclofenac given immediately after endoscopic retrograde cholangiopancreatography can reduce the incidence of acute pancreatitis." | 9.13 | Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. ( Ehsani Ardakani, MJ; Farzin, H; Khorram, H; Khoshbaten, M; Madad, L; Zali, MR, 2008) |
| "The aim of this study was to determine whether prophylactic oral diclofenac will reduce the incidence and the severity of ERCP-induced pancreatitis, especially in high-risk patients." | 9.12 | Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. ( Cheon, YK; Cho, KB; Fogel, EL; Lazzell-Pannell, L; Lehman, GA; McHenry, L; Schmidt, S; Sherman, S; Watkins, JL, 2007) |
| "This trial shows that rectal diclofenac given immediately after endoscopic retrograde cholangiopancreatography can reduce the incidence of acute pancreatitis." | 9.10 | Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. ( Carter, R; Evans, S; Imrie, C; Murray, B; O'Suilleabhain, C, 2003) |
| "Diclofenac and indomethacin are the most studied drugs for preventing post-ERCP pancreatitis (PEP)." | 8.95 | Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled trials. ( Mohácsi, L; Patai, Á; Patai, ÁV; Solymosi, N, 2017) |
| "We evaluated the preventive effect of low-dose diclofenac (25-50 mg) on post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) by propensity score matching analysis." | 8.02 | Rectally Administered Low-Dose Diclofenac Has No Effect on Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Propensity Score Analysis. ( Hori, Y; Ikeura, T; Ito, T; Masuda, M; Mitsuyama, T; Miyoshi, H; Naganuma, M; Nakamaru, K; Okazaki, K; Shimatani, M; Takaoka, M; Takaori, A, 2021) |
| "In this work, no benefit was obtained with diclofenac plus hydration in reducing the number and severity of cases of post-ERCP pancreatitis nor with the other prophylactic measures." | 8.02 | Hydration with Lactated Ringer's solution combined with rectal diclofenac in the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography. ( Almaraz-Gómez, A; Del Olmo Martínez, ML; Velayos Jiménez, B, 2021) |
| "A 50-100 mg rectal dose of diclofenac or indomethacin is recommended for prophylaxis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP); however, limited data are available regarding the appropriate dose to prevent PEP in elderly patients." | 8.02 | A 25 mg rectal dose of diclofenac for prevention of post-ERCP pancreatitis in elderly patients. ( Fujiwara, Y; Fukuda, T; Higashimori, A; Ikeda, D; Maeda, N; Maruyama, H; Mizuno, Y; Morimoto, K; Nakamura, Y; Nakatani, M; Watanabe, T, 2021) |
| "In this large patient cohort in a low-risk unit, diclofenac does not seem to reduce the risk of post-ERCP pancreatitis in patients with PSC." | 7.96 | Diclofenac does not reduce the risk of acute pancreatitis in patients with primary sclerosing cholangitis after endoscopic retrograde cholangiography. ( Färkkilä, M; Jokelainen, K; Koskensalo, V; Kylänpää, L; Lindström, O; Rainio, M; Tenca, A; Udd, M, 2020) |
| "Objective A 50-100-mg rectal dose of nonsteroidal anti-inflammatory drugs (NSAIDs; diclofenac or indomethacin) has been shown to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP)." | 7.88 | The Effectiveness of the Rectal Administration of Low-dose Diclofenac for the Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis. ( Imai, S; Okuno, M; Sato, H; Shiroko, J; Taguchi, D; Takada, J; Thanabashi, S; Yamaguchi, K, 2018) |
| "rectal diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that is used to prevent pancreatitis in high-risk patients during endoscopic retrograde cholangiopancreatography (ERCP)." | 7.88 | Rectal diclofenac does not prevent post-ERCP pancreatitis in consecutive high-risk and low-risk patients. ( Almaraz Gómez, A; Del Olmo Martínez, L; Velayos Jiménez, B, 2018) |
| "Our aim was to evaluate the effect of diclofenac in preventing post-ERCP pancreatitis (PEP) in a high-volume, low-PEP-risk ERCP unit." | 7.85 | Diclofenac Does Not Reduce the Risk of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in Low-Risk Units. ( Kylänpää, L; Lindström, O; Louhimo, J; Rainio, M; Udd, M, 2017) |
| "High patient body weight was associated with a reduced effect of 100 mg diclofenac for prophylaxis of PEP." | 7.83 | Effect of body weight on fixed dose of diclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. ( Hansen, MB; Jørgensen, LN; Leerhøy, B; Nordholm-Carstensen, A; Novovic, S, 2016) |
| "This controlled cohort study suggests that the implementation of a single dose of 100 mg of diclofenac rectally administered significantly reduces the incidence of post-ERCP pancreatitis in an unselected material of patients with native papilla." | 7.80 | Diclofenac is associated with a reduced incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis: results from a Danish cohort study. ( Hansen, MB; Jørgensen, LN; Leerhøy, B; Nordholm-Carstensen, A; Novovic, S, 2014) |
| "A 34 year old female developed acute pancreatitis after commencing diclofenac for a painful arthropathy." | 7.68 | Pancreatitis associated with diclofenac. ( Edward, N; Khan, IH, 1993) |
| "Post-ERCP pancreatitis is usually mild to moderate 95% times." | 7.01 | Is the Combination of Rectal Diclofenac and Intravenous Ringer Lactate Superior to Individual Therapy for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Prospective, Open-Label, Single-Center Randomized Trial. ( Chandnani, S; Debnath, P; Jain, S; Nair, S; Rathi, P; Thanage, R; Udgirkar, S, 2021) |
| "Acute pancreatitis is a major adverse event of endoscopic retrograde cholangiopancreatography (ERCP)." | 6.90 | Combination of Diclofenac and Sublingual Nitrates Is Superior to Diclofenac Alone in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography. ( Akimoto, Y; Fujii, M; Harada, R; Hata, H; Kato, H; Kawai, Y; Matsubara, M; Ogawa, T; Okada, H; Takatani, M; Tomoda, T; Ueki, T; Wato, M, 2019) |
| "Fentanyl was given as a rescue analgesic through a patient-controlled analgesia pump." | 6.90 | Pentazocine, a Kappa-Opioid Agonist, Is Better Than Diclofenac for Analgesia in Acute Pancreatitis: A Randomized Controlled Trial. ( Bopanna, S; Garg, PK; Gupta, S; Jain, S; Mahapatra, SJ; Singh, P; Sreenivas, V; Trikha, A, 2019) |
| "Acute pancreatitis is one of the most common complications of endoscopic retrograde cholangiopancreatography (ERCP)." | 6.79 | Effect of diclofenac on the levels of lipoxin A4 and Resolvin D1 and E1 in the post-ERCP pancreatitis. ( Bao, JJ; Ding, H; Hu, C; Liu, XC; Mei, Q; Xu, JM; Zhao, XW, 2014) |
| "Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP)." | 6.77 | Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. ( Akiyama, T; Ario, K; Fujimoto, M; Kamachi, S; Kawazoe, S; Nakashita, S; Noda, T; Oeda, S; Otsuka, T; Sumida, C; Tabuchi, M, 2012) |
| "Pancreatitis is the most common complication of therapeutic endoscopic retrograde cholangiopancreatography (ERCP), and many pharmacoprophylactic approaches have been suggested, though not without controversy." | 6.77 | Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial. ( Beltsis, A; Chatzimavroudis, G; Dimou, E; Fasoulas, K; Kaltsa, A; Katsinelos, P; Katsinelos, T; Kountouras, J; Paroutoglou, G; Terzoudis, S; Zavos, C, 2012) |
| "Acute pancreatitis is a major adverse event of endoscopic retrograde cholangiopancreatography (ERCP)." | 5.62 | Efficacy of low dose rectal diclofenac for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: Propensity score-matched analysis. ( Fujii, Y; Horiguchi, S; Kato, H; Matsumi, A; Matsumoto, K; Miyamoto, K; Okada, H; Saragai, Y; Tomoda, T; Tsutsumi, K; Uchida, D; Ueta, E; Yamazaki, T, 2021) |
| "Of the total cohort, 8." | 5.62 | Rectal diclofenac for prevention of post-endoscopic retrograde cholangiography pancreatitis. ( Losada, HF; San Martin, PI; Silva, JA; Troncoso, AI, 2021) |
| "High-dose rectal diclofenac suppository and epinephrine spray on duodenal papilla during endoscopic retrograde cholangiopancreatography (ERCP) may reduce the incidence of post-ERCP pancreatitis." | 5.41 | Randomized trial of high-dose rectal diclofenac suppository and epinephrine spray on duodenal papilla for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. ( Ashraf, A; Dar, HA; Javid, G; Khan, MA; Mohammad, S; Shah, A; Sheikh, NA; Singh, B, 2021) |
| "Both diclofenac and tramadol are equally effective in controlling pain in AP with similar safety profile." | 5.34 | Comparison of efficacy of diclofenac and tramadol in relieving pain in patients of acute pancreatitis: A randomized parallel group double blind active controlled pilot study. ( Dhaka, N; Gupta, V; Kochhar, R; Kumar, NS; Muktesh, G; Samanta, J; Samra, T; Sarma, P; Sinha, SK; Yadav, TD, 2020) |
| "We aimed to compare the efficacy of prophylactic, parenterally administered ceftazidime and rectally applied diclofenac sodium for the prophylaxis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP)." | 5.24 | Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial. ( Blažević, I; Bulić, Z; Giljača, V; Hauser, G; Poropat, G; Salkić, N; Štimac, D, 2017) |
| "We carried out a literature search of random controlled trials (RCTs) on preventing post-operative pancreatitis by administration of the anti-inflammatory drugs, indomethacin and diclofenac, following endoscopic retrograde cholangiopancreatography (ERCP)." | 5.22 | Efficacy of Combined Management with Nonsteroidal Anti-inflammatory Drugs for Prevention of Pancreatitis After Endoscopic Retrograde Cholangiography: a Bayesian Network Meta-analysis. ( Du, F; Fan, H; Ren, L; Yang, X; Yuan, W; Zhang, L; Zhang, Y, 2022) |
| "Routine rectal administration of 100 mg of diclofenac or indomethacin was demonstrated to be an effective prevention method to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis." | 5.22 | The Incidence and Severity of Post-ERCP Pancreatitis in Patients Receiving Standard Administration of NSAIDs: a Systematic Review and Meta-analysis. ( Chen, Z; Guo, X; Kang, X; Lou, L; Lu, Y; Luo, H; Pan, Y; Zhou, Z, 2022) |
| "Prophylaxis with diclofenac given rectally or intramuscularly is an effective option for the management of post-ERCP pancreatitis." | 5.22 | Rectal or intramuscular diclofenac reduces the incidence of pancreatitis afterendoscopic retrograde cholangiopancreatography. ( Ataseven, H; Biyik, M; Çifçi, S; Demir, A; Polat, İ; Uçar, E; Uçar, R, 2016) |
| "We aimed to investigate the preventive effect of oral diclofenac on pancreatitis after ERCP in a multicenter, randomized, prospective, placebo-controlled, double-blind trial." | 5.22 | No Benefit of Oral Diclofenac on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. ( Doi, S; Hayashi, T; Hisai, H; Ishiwatari, H; Iwashita, T; Kato, J; Kawakami, H; Kawakubo, K; Matsusaki, S; Ono, M; Sakamoto, N; Sonoda, T; Urata, T; Yasuda, I, 2016) |
| "Combination therapy with udenafil and aceclofenac is not effective for the prevention of post-ERCP pancreatitis." | 5.20 | Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter study. ( Cheon, YK; Choi, JS; Do, JH; Lee, TY; Oh, HC; Song, TJ, 2015) |
| "To assess the efficacy of intramuscular diclofenac and fluid replacement for prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis." | 5.14 | Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis. ( Demirkan, H; Saritas, U; Senol, A, 2009) |
| "This trial shows that rectal diclofenac given immediately after endoscopic retrograde cholangiopancreatography can reduce the incidence of acute pancreatitis." | 5.13 | Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. ( Ehsani Ardakani, MJ; Farzin, H; Khorram, H; Khoshbaten, M; Madad, L; Zali, MR, 2008) |
| "The aim of this study was to determine whether prophylactic oral diclofenac will reduce the incidence and the severity of ERCP-induced pancreatitis, especially in high-risk patients." | 5.12 | Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. ( Cheon, YK; Cho, KB; Fogel, EL; Lazzell-Pannell, L; Lehman, GA; McHenry, L; Schmidt, S; Sherman, S; Watkins, JL, 2007) |
| "This trial shows that rectal diclofenac given immediately after endoscopic retrograde cholangiopancreatography can reduce the incidence of acute pancreatitis." | 5.10 | Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. ( Carter, R; Evans, S; Imrie, C; Murray, B; O'Suilleabhain, C, 2003) |
| "Diclofenac and indomethacin are the most studied drugs for preventing post-ERCP pancreatitis (PEP)." | 4.95 | Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled trials. ( Mohácsi, L; Patai, Á; Patai, ÁV; Solymosi, N, 2017) |
| "Pancreatic stent placement, rectal diclofenac, and bolus administration of somatostatin appear to be most effective in preventing post-ERCP pancreatitis." | 4.93 | Endoscopic and pharmacological treatment for prophylaxis against postendoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis and systematic review. ( Bulajic, M; Faleschini, G; Panic, N; Vadalà di Prampero, SF, 2016) |
| "In this work, no benefit was obtained with diclofenac plus hydration in reducing the number and severity of cases of post-ERCP pancreatitis nor with the other prophylactic measures." | 4.02 | Hydration with Lactated Ringer's solution combined with rectal diclofenac in the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography. ( Almaraz-Gómez, A; Del Olmo Martínez, ML; Velayos Jiménez, B, 2021) |
| "We evaluated the preventive effect of low-dose diclofenac (25-50 mg) on post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) by propensity score matching analysis." | 4.02 | Rectally Administered Low-Dose Diclofenac Has No Effect on Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Propensity Score Analysis. ( Hori, Y; Ikeura, T; Ito, T; Masuda, M; Mitsuyama, T; Miyoshi, H; Naganuma, M; Nakamaru, K; Okazaki, K; Shimatani, M; Takaoka, M; Takaori, A, 2021) |
| "A 50-100 mg rectal dose of diclofenac or indomethacin is recommended for prophylaxis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP); however, limited data are available regarding the appropriate dose to prevent PEP in elderly patients." | 4.02 | A 25 mg rectal dose of diclofenac for prevention of post-ERCP pancreatitis in elderly patients. ( Fujiwara, Y; Fukuda, T; Higashimori, A; Ikeda, D; Maeda, N; Maruyama, H; Mizuno, Y; Morimoto, K; Nakamura, Y; Nakatani, M; Watanabe, T, 2021) |
| "In this large patient cohort in a low-risk unit, diclofenac does not seem to reduce the risk of post-ERCP pancreatitis in patients with PSC." | 3.96 | Diclofenac does not reduce the risk of acute pancreatitis in patients with primary sclerosing cholangitis after endoscopic retrograde cholangiography. ( Färkkilä, M; Jokelainen, K; Koskensalo, V; Kylänpää, L; Lindström, O; Rainio, M; Tenca, A; Udd, M, 2020) |
| "rectal diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that is used to prevent pancreatitis in high-risk patients during endoscopic retrograde cholangiopancreatography (ERCP)." | 3.88 | Rectal diclofenac does not prevent post-ERCP pancreatitis in consecutive high-risk and low-risk patients. ( Almaraz Gómez, A; Del Olmo Martínez, L; Velayos Jiménez, B, 2018) |
| "Objective A 50-100-mg rectal dose of nonsteroidal anti-inflammatory drugs (NSAIDs; diclofenac or indomethacin) has been shown to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP)." | 3.88 | The Effectiveness of the Rectal Administration of Low-dose Diclofenac for the Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis. ( Imai, S; Okuno, M; Sato, H; Shiroko, J; Taguchi, D; Takada, J; Thanabashi, S; Yamaguchi, K, 2018) |
| "The NSAIDs ibuprofen and diclofenac were administered to C57BL/6 mice after induction of pancreatitis with serial injections of cerulein." | 3.88 | Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon inflammatory injury and mitogenic stimulation. ( Bombardo, M; Chen, R; Graf, R; Malagola, E; Rudnicka, A; Sonda, S, 2018) |
| "Our aim was to evaluate the effect of diclofenac in preventing post-ERCP pancreatitis (PEP) in a high-volume, low-PEP-risk ERCP unit." | 3.85 | Diclofenac Does Not Reduce the Risk of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in Low-Risk Units. ( Kylänpää, L; Lindström, O; Louhimo, J; Rainio, M; Udd, M, 2017) |
| "High patient body weight was associated with a reduced effect of 100 mg diclofenac for prophylaxis of PEP." | 3.83 | Effect of body weight on fixed dose of diclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. ( Hansen, MB; Jørgensen, LN; Leerhøy, B; Nordholm-Carstensen, A; Novovic, S, 2016) |
| "This controlled cohort study suggests that the implementation of a single dose of 100 mg of diclofenac rectally administered significantly reduces the incidence of post-ERCP pancreatitis in an unselected material of patients with native papilla." | 3.80 | Diclofenac is associated with a reduced incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis: results from a Danish cohort study. ( Hansen, MB; Jørgensen, LN; Leerhøy, B; Nordholm-Carstensen, A; Novovic, S, 2014) |
| "A 34 year old female developed acute pancreatitis after commencing diclofenac for a painful arthropathy." | 3.68 | Pancreatitis associated with diclofenac. ( Edward, N; Khan, IH, 1993) |
| "Post-ERCP pancreatitis is usually mild to moderate 95% times." | 3.01 | Is the Combination of Rectal Diclofenac and Intravenous Ringer Lactate Superior to Individual Therapy for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Prospective, Open-Label, Single-Center Randomized Trial. ( Chandnani, S; Debnath, P; Jain, S; Nair, S; Rathi, P; Thanage, R; Udgirkar, S, 2021) |
| "Acute pancreatitis is a major adverse event of endoscopic retrograde cholangiopancreatography (ERCP)." | 2.90 | Combination of Diclofenac and Sublingual Nitrates Is Superior to Diclofenac Alone in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography. ( Akimoto, Y; Fujii, M; Harada, R; Hata, H; Kato, H; Kawai, Y; Matsubara, M; Ogawa, T; Okada, H; Takatani, M; Tomoda, T; Ueki, T; Wato, M, 2019) |
| "Fentanyl was given as a rescue analgesic through a patient-controlled analgesia pump." | 2.90 | Pentazocine, a Kappa-Opioid Agonist, Is Better Than Diclofenac for Analgesia in Acute Pancreatitis: A Randomized Controlled Trial. ( Bopanna, S; Garg, PK; Gupta, S; Jain, S; Mahapatra, SJ; Singh, P; Sreenivas, V; Trikha, A, 2019) |
| "Acute pancreatitis is one of the most common complications of endoscopic retrograde cholangiopancreatography (ERCP)." | 2.79 | Effect of diclofenac on the levels of lipoxin A4 and Resolvin D1 and E1 in the post-ERCP pancreatitis. ( Bao, JJ; Ding, H; Hu, C; Liu, XC; Mei, Q; Xu, JM; Zhao, XW, 2014) |
| "Pancreatitis is the most common complication of therapeutic endoscopic retrograde cholangiopancreatography (ERCP), and many pharmacoprophylactic approaches have been suggested, though not without controversy." | 2.77 | Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial. ( Beltsis, A; Chatzimavroudis, G; Dimou, E; Fasoulas, K; Kaltsa, A; Katsinelos, P; Katsinelos, T; Kountouras, J; Paroutoglou, G; Terzoudis, S; Zavos, C, 2012) |
| "Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP)." | 2.77 | Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. ( Akiyama, T; Ario, K; Fujimoto, M; Kamachi, S; Kawazoe, S; Nakashita, S; Noda, T; Oeda, S; Otsuka, T; Sumida, C; Tabuchi, M, 2012) |
| "Acute pancreatitis is a major adverse event of endoscopic retrograde cholangiopancreatography (ERCP)." | 1.62 | Efficacy of low dose rectal diclofenac for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: Propensity score-matched analysis. ( Fujii, Y; Horiguchi, S; Kato, H; Matsumi, A; Matsumoto, K; Miyamoto, K; Okada, H; Saragai, Y; Tomoda, T; Tsutsumi, K; Uchida, D; Ueta, E; Yamazaki, T, 2021) |
| "Of the total cohort, 8." | 1.62 | Rectal diclofenac for prevention of post-endoscopic retrograde cholangiography pancreatitis. ( Losada, HF; San Martin, PI; Silva, JA; Troncoso, AI, 2021) |
| "Acute pancreatitis was observed in 13." | 1.42 | Assessment of Pharmacological Prophylaxis for Acute Pancreatitis Following ERCP in Patients with Choledoholithiasis. ( Kołomecki, K; Łubowska-Pająk, E, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.59) | 18.2507 |
| 2000's | 7 (11.11) | 29.6817 |
| 2010's | 37 (58.73) | 24.3611 |
| 2020's | 18 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Takaori, A | 1 |
| Ikeura, T | 1 |
| Hori, Y | 1 |
| Ito, T | 1 |
| Nakamaru, K | 1 |
| Masuda, M | 2 |
| Mitsuyama, T | 1 |
| Miyoshi, H | 1 |
| Shimatani, M | 1 |
| Takaoka, M | 1 |
| Okazaki, K | 1 |
| Naganuma, M | 1 |
| Thanage, R | 1 |
| Jain, S | 3 |
| Chandnani, S | 1 |
| Udgirkar, S | 1 |
| Nair, S | 1 |
| Debnath, P | 1 |
| Rathi, P | 1 |
| Dar, HA | 1 |
| Shah, A | 1 |
| Javid, G | 1 |
| Khan, MA | 1 |
| Singh, B | 1 |
| Sheikh, NA | 1 |
| Ashraf, A | 1 |
| Mohammad, S | 1 |
| Park, TY | 2 |
| Kang, H | 2 |
| Choi, GJ | 2 |
| Oh, HC | 3 |
| Du, F | 1 |
| Zhang, Y | 1 |
| Yang, X | 1 |
| Zhang, L | 1 |
| Yuan, W | 1 |
| Fan, H | 1 |
| Ren, L | 1 |
| Kang, X | 1 |
| Guo, X | 2 |
| Chen, Z | 1 |
| Zhou, Z | 1 |
| Luo, H | 1 |
| Lu, Y | 1 |
| Lou, L | 1 |
| Pan, Y | 1 |
| Koshitani, T | 1 |
| Konaka, Y | 1 |
| Ohishi, T | 1 |
| Yasuda, T | 1 |
| Morinushi, T | 1 |
| Mita, M | 1 |
| Nakano, K | 1 |
| Fuki, S | 1 |
| Nakagawa, S | 1 |
| Sakai, H | 3 |
| Iwai, N | 3 |
| Sakagami, J | 3 |
| Okuda, T | 3 |
| Ohara, T | 3 |
| Hattori, C | 3 |
| Taniguchi, M | 3 |
| Oka, K | 3 |
| Hara, T | 3 |
| Tsuji, T | 3 |
| Komaki, T | 3 |
| Kagawa, K | 3 |
| Dohi, O | 3 |
| Yasuda, H | 3 |
| Konishi, H | 3 |
| Itoh, Y | 3 |
| Zhang, ZF | 1 |
| Shimamura, T | 1 |
| Miyahara, K | 1 |
| Takamori, A | 1 |
| Hidaka, H | 1 |
| Ito, Y | 1 |
| Fujimoto, S | 1 |
| Takedomi, H | 1 |
| Tsuruoka, N | 1 |
| Sakata, Y | 1 |
| Eguchi, Y | 1 |
| Node, K | 1 |
| Noda, T | 2 |
| Fujimoto, K | 1 |
| Kumar, NS | 1 |
| Muktesh, G | 1 |
| Samra, T | 1 |
| Sarma, P | 1 |
| Samanta, J | 1 |
| Sinha, SK | 1 |
| Dhaka, N | 1 |
| Yadav, TD | 1 |
| Gupta, V | 1 |
| Kochhar, R | 1 |
| Katoh, T | 1 |
| Kawashima, K | 1 |
| Fukuba, N | 1 |
| Masuda, S | 1 |
| Kobatake, H | 1 |
| Masaki, K | 1 |
| Araki, Y | 1 |
| Kawano, K | 1 |
| Nishi, K | 1 |
| Takenaka, M | 1 |
| Ishihara, S | 1 |
| Kinoshita, Y | 1 |
| Koskensalo, V | 1 |
| Tenca, A | 1 |
| Udd, M | 2 |
| Lindström, O | 2 |
| Rainio, M | 2 |
| Jokelainen, K | 1 |
| Kylänpää, L | 2 |
| Färkkilä, M | 1 |
| Ang, TL | 2 |
| Del Olmo Martínez, ML | 1 |
| Velayos Jiménez, B | 2 |
| Almaraz-Gómez, A | 1 |
| Tomoda, T | 2 |
| Kato, H | 2 |
| Miyamoto, K | 1 |
| Matsumi, A | 1 |
| Ueta, E | 1 |
| Fujii, Y | 1 |
| Saragai, Y | 1 |
| Yamazaki, T | 1 |
| Uchida, D | 1 |
| Matsumoto, K | 1 |
| Horiguchi, S | 1 |
| Tsutsumi, K | 1 |
| Okada, H | 2 |
| Losada, HF | 1 |
| San Martin, PI | 1 |
| Troncoso, AI | 1 |
| Silva, JA | 1 |
| Lehman, GA | 2 |
| Maeda, N | 1 |
| Higashimori, A | 1 |
| Nakatani, M | 1 |
| Mizuno, Y | 1 |
| Nakamura, Y | 1 |
| Ikeda, D | 1 |
| Maruyama, H | 1 |
| Morimoto, K | 1 |
| Fukuda, T | 1 |
| Watanabe, T | 1 |
| Fujiwara, Y | 1 |
| Louhimo, J | 1 |
| Bombardo, M | 1 |
| Malagola, E | 1 |
| Chen, R | 1 |
| Rudnicka, A | 1 |
| Graf, R | 1 |
| Sonda, S | 1 |
| Okuno, M | 1 |
| Shiroko, J | 1 |
| Taguchi, D | 1 |
| Yamaguchi, K | 1 |
| Takada, J | 1 |
| Imai, S | 1 |
| Sato, H | 1 |
| Thanabashi, S | 1 |
| Del Olmo Martínez, L | 1 |
| Almaraz Gómez, A | 1 |
| Hollerbach, S | 1 |
| Lyu, Y | 1 |
| Cheng, Y | 1 |
| Wang, B | 1 |
| Xu, Y | 1 |
| Du, W | 1 |
| Ueki, T | 1 |
| Akimoto, Y | 1 |
| Hata, H | 1 |
| Fujii, M | 1 |
| Harada, R | 1 |
| Ogawa, T | 1 |
| Wato, M | 1 |
| Takatani, M | 1 |
| Matsubara, M | 1 |
| Kawai, Y | 1 |
| Mahapatra, SJ | 1 |
| Bopanna, S | 1 |
| Gupta, S | 1 |
| Singh, P | 1 |
| Trikha, A | 1 |
| Sreenivas, V | 1 |
| Garg, PK | 1 |
| Sethi, S | 1 |
| Sethi, N | 1 |
| Wadhwa, V | 1 |
| Garud, S | 1 |
| Brown, A | 1 |
| Leerhøy, B | 2 |
| Nordholm-Carstensen, A | 2 |
| Novovic, S | 2 |
| Hansen, MB | 2 |
| Jørgensen, LN | 2 |
| Zhao, XW | 1 |
| Bao, JJ | 1 |
| Hu, C | 1 |
| Ding, H | 1 |
| Liu, XC | 1 |
| Mei, Q | 1 |
| Xu, JM | 1 |
| Dumonceau, JM | 1 |
| Andriulli, A | 1 |
| Elmunzer, BJ | 2 |
| Mariani, A | 1 |
| Meister, T | 1 |
| Deviere, J | 1 |
| Marek, T | 1 |
| Baron, TH | 1 |
| Hassan, C | 1 |
| Testoni, PA | 2 |
| Kapral, C | 1 |
| Nicolás-Pérez, D | 1 |
| Castilla-Rodríguez, I | 1 |
| Gimeno-García, AZ | 1 |
| Romero-García, R | 1 |
| Núñez-Díaz, V | 1 |
| Quintero, E | 1 |
| Park, SW | 2 |
| Chung, MJ | 1 |
| Oh, TG | 1 |
| Park, JY | 1 |
| Bang, S | 1 |
| Song, SY | 1 |
| Nicholson, JA | 1 |
| Greenhalf, W | 1 |
| Jackson, R | 1 |
| Cox, TF | 1 |
| Butler, JV | 1 |
| Hanna, T | 1 |
| Harrison, S | 1 |
| Grocock, CJ | 1 |
| Halloran, CM | 1 |
| Howes, NR | 1 |
| Raraty, MG | 1 |
| Ghaneh, P | 1 |
| Johnstone, M | 1 |
| Sarkar, S | 1 |
| Smart, HL | 1 |
| Evans, JC | 1 |
| Aithal, GP | 1 |
| Sutton, R | 1 |
| Neoptolemos, JP | 1 |
| Lombard, MG | 1 |
| Lua, GW | 1 |
| Muthukaruppan, R | 1 |
| Menon, J | 1 |
| Yoshihara, T | 1 |
| Horimoto, M | 1 |
| Kitamura, T | 1 |
| Osugi, N | 1 |
| Ikezoe, T | 1 |
| Kotani, K | 1 |
| Sanada, T | 1 |
| Higashi, C | 1 |
| Yamaguchi, D | 1 |
| Ota, M | 1 |
| Mizuno, T | 1 |
| Gotoh, Y | 1 |
| Okuda, Y | 1 |
| Suzuki, K | 1 |
| Patai, Á | 2 |
| Patai, ÁV | 2 |
| Solymosi, N | 2 |
| Tulassay, Z | 1 |
| Herszényi, L | 1 |
| Shah, T | 1 |
| Zfass, A | 1 |
| Schubert, ML | 1 |
| Saritas, U | 2 |
| Ustundag, Y | 1 |
| Rustagi, T | 1 |
| Njei, B | 1 |
| Lee, TY | 1 |
| Choi, JS | 1 |
| Song, TJ | 1 |
| Do, JH | 1 |
| Cheon, YK | 2 |
| Łubowska-Pająk, E | 1 |
| Kołomecki, K | 1 |
| Hauser, G | 1 |
| Blažević, I | 1 |
| Salkić, N | 1 |
| Poropat, G | 1 |
| Giljača, V | 1 |
| Bulić, Z | 1 |
| Štimac, D | 1 |
| Ishiwatari, H | 1 |
| Urata, T | 1 |
| Yasuda, I | 1 |
| Matsusaki, S | 1 |
| Hisai, H | 1 |
| Kawakami, H | 1 |
| Ono, M | 1 |
| Iwashita, T | 1 |
| Doi, S | 1 |
| Kawakubo, K | 1 |
| Hayashi, T | 1 |
| Sonoda, T | 1 |
| Sakamoto, N | 1 |
| Kato, J | 1 |
| Uçar, R | 1 |
| Biyik, M | 1 |
| Uçar, E | 1 |
| Polat, İ | 1 |
| Çifçi, S | 1 |
| Ataseven, H | 1 |
| Demir, A | 1 |
| Kwek, AB | 1 |
| Song, M | 1 |
| Li, JW | 1 |
| Thurairajah, PH | 1 |
| Vadalà di Prampero, SF | 1 |
| Faleschini, G | 1 |
| Panic, N | 1 |
| Bulajic, M | 1 |
| Mohammad Alizadeh, AH | 1 |
| Abbasinazari, M | 1 |
| Hatami, B | 1 |
| Abdi, S | 1 |
| Ahmadpour, F | 1 |
| Dabir, S | 1 |
| Nematollahi, A | 1 |
| Fatehi, S | 1 |
| Pourhoseingholi, MA | 1 |
| Mohácsi, L | 1 |
| Senol, A | 1 |
| Demirkan, H | 1 |
| Katsinelos, P | 1 |
| Fasoulas, K | 1 |
| Paroutoglou, G | 1 |
| Chatzimavroudis, G | 1 |
| Beltsis, A | 1 |
| Terzoudis, S | 1 |
| Katsinelos, T | 1 |
| Dimou, E | 1 |
| Zavos, C | 1 |
| Kaltsa, A | 1 |
| Kountouras, J | 1 |
| Otsuka, T | 1 |
| Kawazoe, S | 1 |
| Nakashita, S | 1 |
| Kamachi, S | 1 |
| Oeda, S | 1 |
| Sumida, C | 1 |
| Akiyama, T | 1 |
| Ario, K | 1 |
| Fujimoto, M | 1 |
| Tabuchi, M | 1 |
| Murray, B | 1 |
| Carter, R | 1 |
| Imrie, C | 1 |
| Evans, S | 1 |
| O'Suilleabhain, C | 1 |
| Freeman, ML | 1 |
| Oiofinlade, O | 1 |
| Madanick, RD | 1 |
| O'Loughlin, CJ | 1 |
| Barkin, JS | 1 |
| Khoshbaten, M | 1 |
| Khorram, H | 1 |
| Madad, L | 1 |
| Ehsani Ardakani, MJ | 1 |
| Farzin, H | 1 |
| Zali, MR | 1 |
| Cho, KB | 1 |
| Watkins, JL | 1 |
| McHenry, L | 1 |
| Fogel, EL | 1 |
| Sherman, S | 1 |
| Schmidt, S | 1 |
| Lazzell-Pannell, L | 1 |
| Khan, IH | 1 |
| Edward, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rectal Disclofenac Versus Indomethacin for Prevention of Post-ERCP Pancreatitis (DIPPP): A Multicentre, Double-blind, Randomised, Controlled Trial[NCT05947461] | 3,612 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | |||
| A Randomized Trial Comparing Rectal Indomethacin Alone Versus a Combination of Rectal Indomethacin and Oral Tacrolimus for Post-ERCP Pancreatitis Prophylaxis[NCT05252754] | Phase 3 | 4,874 participants (Anticipated) | Interventional | 2023-01-18 | Recruiting | ||
| Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate to Prevent Post-ERCP Pancreatitis: a Multicentre, Non-inferiority, Double-blind, Randomised Trial[NCT04425993] | 2,700 participants (Actual) | Interventional | 2020-07-01 | Active, not recruiting | |||
| Endoscopic Retrograde Cholangiopancreatography (ERCP)-Induced and Non-ERCP Induced Acute Pancreatitis: Two Distinct Clinical and Immunological Entities?[NCT02602574] | 66 participants (Anticipated) | Observational | 2018-01-31 | Enrolling by invitation | |||
| Is Needle Knife Fistulotomy An Effective First Step Strategy For All ERCPs?[NCT03698266] | 84 participants (Actual) | Interventional | 2018-11-23 | Completed | |||
| Comparative Evaluation of Standard Prophylaxis Versus Divided-dose NSAIDs or Hybrid NSAID and N-acetylcysteine Therapy for the Prevention of Post-ERCP Pancreatitis[NCT03708458] | Phase 4 | 250 participants (Anticipated) | Interventional | 2017-04-01 | Recruiting | ||
| Combination of Rectal Indomethacin and Pancreatic Duct Stenting Versus Indomethacin Alone in Preventing Post-ERCP Pancreatitis in Patients With Difficult Cannulation[NCT04340687] | 664 participants (Actual) | Observational | 2020-01-01 | Completed | |||
| Risk Factors Related to Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in High-risk Patients Who Underwent ERCP and Received Prophylactic Rectal Indomethacin[NCT02709421] | 790 participants (Actual) | Observational | 2016-02-29 | Completed | |||
| Effect of Papillary Epinephrine Spraying on Post-ERCP Pancreatitis in Patients Received Rectal Indomethacin: A Multi-center, Double-blind, Randomized Controlled Trial[NCT03057769] | 3,300 participants (Actual) | Interventional | 2017-02-01 | Terminated (stopped due to This study was terminated because of an interim analysis suggesting futility of papillary epinephrine spraying in PEP prevention.) | |||
| [NCT01717599] | 343 participants (Actual) | Interventional | 2012-08-29 | Completed | |||
| A Randomized Double-blinded Trial Comparing the Clinical Efficacy and Pharmacokinetic Parameters of Oral Diclofenac and Intramuscular Diclofenac in Patients With Acute Limb Injuries[NCT03472339] | Phase 4 | 300 participants (Anticipated) | Interventional | 2018-01-15 | Recruiting | ||
| Propofol Sedation During Endoscopic Retrograde Cholangiopancreatography: A Comparison Between Conventional Versus Bispectral Index Guided Approach and Effect of Diclofenac Sodium Along With Topical Pharyngeal Anaesthesia[NCT04860167] | 90 participants (Actual) | Interventional | 2018-09-10 | Completed | |||
| A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis[NCT02465138] | Phase 4 | 0 participants (Actual) | Interventional | 2023-11-30 | Withdrawn (stopped due to Lack of Funding) | ||
| Comparative Effectiveness Between Rectally Administered Indomethacin and Pancreatic Stenting in the Prevention of Post Endoscopic Retrograde Cholangio-panceaticography (ERCP) Pancreatitis: a Randomized Trial[NCT03713879] | Phase 3 | 1,734 participants (Anticipated) | Interventional | 2019-03-21 | Recruiting | ||
| Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)[NCT02111707] | Phase 4 | 534 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| [NCT00121901] | Phase 3 | 1,600 participants (Anticipated) | Interventional | 2004-10-31 | Completed | ||
| Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) - Induced Pancreatitis Using Aggressive Lactated Ringer's Infusion and/or Rectal Indomethacin[NCT02641561] | Phase 3 | 192 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | days (Mean) |
|---|---|
| A (NS+Placebo) | 2.3 |
| B (NS+IND) | 2.2 |
| C (LR+Placebo) | 1.9 |
| D (LR+IND) | 4.3 |
(NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
(NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 6 |
| B (NS+IND) | 2 |
| C (LR+Placebo) | 2 |
| D (LR+IND) | 1 |
amylase or lipase (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 10 |
| B (NS+IND) | 6 |
| C (LR+Placebo) | 9 |
| D (LR+IND) | 3 |
Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 1 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 1 |
bilateral opacities on chest imaging not explained by other lung pathology, respiratory failure not explained by heart failure or volume, and overload and a pulmonary arterial oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio under 300, PaO2/FiO2 ratio is the partial pressure arterial oxygen and fraction of inspired oxygen (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 1 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
(NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 1 |
| B (NS+IND) | 2 |
| C (LR+Placebo) | 2 |
| D (LR+IND) | 1 |
creatinine > 1.5 milligrams/deciliter (mg/dL) (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 1 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
INR > 1.5 (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 1 |
Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
(NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 6 |
| B (NS+IND) | 2 |
| C (LR+Placebo) | 2 |
| D (LR+IND) | 1 |
positive blood culture (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
> 10% immature neutrophils (band forms). (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 10 |
| B (NS+IND) | 6 |
| C (LR+Placebo) | 9 |
| D (LR+IND) | 3 |
Heart rate > 90 beats per minutes (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 10 |
| B (NS+IND) | 6 |
| C (LR+Placebo) | 9 |
| D (LR+IND) | 3 |
PaCO2 < 4.3 kilopascal (kPa) (32 mmHg) (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
Respiratory rate > 20 breaths per minute (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 10 |
| B (NS+IND) | 6 |
| C (LR+Placebo) | 9 |
| D (LR+IND) | 3 |
Temperature < 36°C(96.8°F) or > 38°C(100.4°F) (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 10 |
| B (NS+IND) | 6 |
| C (LR+Placebo) | 9 |
| D (LR+IND) | 3 |
white blood cell (WBC) count < 4000 cells/mm³ (4 x 109 cells/L) (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
10 reviews available for diclofenac and Acute Edematous Pancreatitis
| Article | Year |
|---|---|
Rectal NSAIDs-based combination modalities are superior to single modalities for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a network meta-analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2022 |
Efficacy of Combined Management with Nonsteroidal Anti-inflammatory Drugs for Prevention of Pancreatitis After Endoscopic Retrograde Cholangiography: a Bayesian Network Meta-analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2022 |
The Incidence and Severity of Post-ERCP Pancreatitis in Patients Receiving Standard Administration of NSAIDs: a Systematic Review and Meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2022 |
Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis with a combination of pharmacological agents based on rectal non-steroidal anti-inflammatory drugs: A systematic review and network meta-analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2021 |
What is impact of nonsteroidal anti-inflammatory drugs in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2018 |
A meta-analysis on the role of rectal diclofenac and indomethacin in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
[Prevention of acute pancreatitis following endoscopic retrograde cholangiopancreatography].
Topics: Acute Disease; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Catheterization; Cho | 2015 |
Factors Affecting the Efficacy of Nonsteroidal Anti-inflammatory Drugs in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Systematic Review and Meta-analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Chi-Square Distribution; Cholangiop | 2015 |
Endoscopic and pharmacological treatment for prophylaxis against postendoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis and systematic review.
Topics: Administration, Intravenous; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholan | 2016 |
Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled trials.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2017 |
21 trials available for diclofenac and Acute Edematous Pancreatitis
| Article | Year |
|---|---|
Is the Combination of Rectal Diclofenac and Intravenous Ringer Lactate Superior to Individual Therapy for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Prospective, Open-Label, Single-Center Randomized Trial.
Topics: Administration, Intravenous; Administration, Rectal; Cholangiopancreatography, Endoscopic Retrograde | 2021 |
Randomized trial of high-dose rectal diclofenac suppository and epinephrine spray on duodenal papilla for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2021 |
Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Using Temporary Pancreatic Stents Versus Rectal Nonsteroidal Anti-inflammatory Drugs: A Randomized Controlled Trial.
Topics: Administration, Rectal; Amylases; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, | 2022 |
Comparison of efficacy of diclofenac and tramadol in relieving pain in patients of acute pancreatitis: A randomized parallel group double blind active controlled pilot study.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Humans; Pai | 2020 |
Low-dose rectal diclofenac does not prevent post-ERCP pancreatitis in low- or high-risk patients.
Topics: Administration, Rectal; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cholangiop | 2020 |
Combination of Diclofenac and Sublingual Nitrates Is Superior to Diclofenac Alone in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography.
Topics: Administration, Sublingual; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, | 2019 |
Pentazocine, a Kappa-Opioid Agonist, Is Better Than Diclofenac for Analgesia in Acute Pancreatitis: A Randomized Controlled Trial.
Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dose-Response Relationship, | 2019 |
Effect of diclofenac on the levels of lipoxin A4 and Resolvin D1 and E1 in the post-ERCP pancreatitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2014 |
Intramuscular diclofenac for the prevention of post-ERCP pancreatitis: a randomized trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograd | 2015 |
Can Rectal Diclofenac Prevent Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis?
Topics: Administration, Rectal; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatograp | 2015 |
Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-S | 2015 |
Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.
Topics: Abdominal Pain; Administration, Intravenous; Administration, Rectal; Adult; Aged; Aged, 80 and over; | 2017 |
No Benefit of Oral Diclofenac on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amylases; Anti-Inflammatory Agents, Non-Steroidal; Au | 2016 |
Rectal or intramuscular diclofenac reduces the incidence of pancreatitis afterendoscopic retrograde cholangiopancreatography.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2016 |
Comparison of rectal indomethacin, diclofenac, and naproxen for the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Administration, Rectal; Adult; Aged; Amylases; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; | 2017 |
Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Dicl | 2009 |
Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Amylases; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography | 2012 |
Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Dicl | 2012 |
Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Dicl | 2012 |
Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Dicl | 2012 |
Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Dicl | 2012 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Acute Disease; Administration, Rectal; Adult; Aged; Amylases; Anti-Inflammatory Agents, Non-Steroida | 2008 |
Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Acute Disease; Administration, Rectal; Adult; Aged; Amylases; Anti-Inflammatory Agents, Non-Steroida | 2008 |
Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Acute Disease; Administration, Rectal; Adult; Aged; Amylases; Anti-Inflammatory Agents, Non-Steroida | 2008 |
Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Acute Disease; Administration, Rectal; Adult; Aged; Amylases; Anti-Inflammatory Agents, Non-Steroida | 2008 |
Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Fema | 2007 |
32 other studies available for diclofenac and Acute Edematous Pancreatitis
| Article | Year |
|---|---|
Rectally Administered Low-Dose Diclofenac Has No Effect on Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Propensity Score Analysis.
Topics: Administration, Rectal; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, End | 2021 |
Rectal administration of low-dose diclofenac does not reduce post-endoscopic retrograde cholangiopancreatography pancreatitis: a propensity score matching analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2023 |
Rectal administration of low-dose diclofenac does not reduce post-endoscopic retrograde cholangiopancreatography pancreatitis: a propensity score matching analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2023 |
Rectal administration of low-dose diclofenac does not reduce post-endoscopic retrograde cholangiopancreatography pancreatitis: a propensity score matching analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2023 |
Rectal administration of low-dose diclofenac does not reduce post-endoscopic retrograde cholangiopancreatography pancreatitis: a propensity score matching analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2023 |
More Evidence Needed on the Combination of Diclofenac and Sublingual Nitrates in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2019 |
Risk Factors for Post-Endoscopic Retrograde Pancreatography Pancreatitis: A Retrospective Chart Review in a Regional Hospital in Japan.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatogra | 2020 |
Diclofenac does not reduce the risk of acute pancreatitis in patients with primary sclerosing cholangitis after endoscopic retrograde cholangiography.
Topics: Administration, Rectal; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Contr | 2020 |
Mitigating the risk of post-ERCP pancreatitis: Science and clinical practice.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2020 |
Hydration with Lactated Ringer's solution combined with rectal diclofenac in the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Administration, Rectal; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatograp | 2021 |
Efficacy of low dose rectal diclofenac for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: Propensity score-matched analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrogr | 2021 |
Rectal diclofenac for prevention of post-endoscopic retrograde cholangiography pancreatitis.
Topics: Acute Disease; Adult; Aged; Cholangiography; Cholangiopancreatography, Endoscopic Retrograde; Diclof | 2021 |
A 25 mg rectal dose of diclofenac for prevention of post-ERCP pancreatitis in elderly patients.
Topics: Aged; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac; Humans; Indomethacin; Pancreatiti | 2021 |
Diclofenac Does Not Reduce the Risk of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in Low-Risk Units.
Topics: Administration, Rectal; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-St | 2017 |
Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon inflammatory injury and mitogenic stimulation.
Topics: Acinar Cells; Animals; Cell Differentiation; Cell Proliferation; Ceruletide; Cytokines; Diclofenac; | 2018 |
The Effectiveness of the Rectal Administration of Low-dose Diclofenac for the Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis.
Topics: Administration, Rectal; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cholangiop | 2018 |
Rectal diclofenac does not prevent post-ERCP pancreatitis in consecutive high-risk and low-risk patients.
Topics: Administration, Rectal; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-S | 2018 |
["Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled trials"].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2018 |
Diclofenac is associated with a reduced incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis: results from a Danish cohort study.
Topics: Acute Disease; Administration, Rectal; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholang | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a cost-effectiveness analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2015 |
Incidence of post-ERCP pancreatitis from direct pancreatic juice collection in hereditary pancreatitis and familial pancreatic cancer before and after the introduction of prophylactic pancreatic stents and rectal diclofenac.
Topics: Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers, Tumor; Cholangio | 2015 |
Nonsteroidal anti-inflammatory drugs for preventing post-ERCP pancreatitis: why rectal and not intramuscular?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2015 |
[In Process Citation].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2015 |
25 mg versus 50 mg dose of rectal diclofenac for prevention of post-ERCP pancreatitis in Japanese patients: a retrospective study.
Topics: Administration, Rectal; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cholangiop | 2015 |
Chemoprevention of Post-ERCP Pancreatitis with Rectal NSAIDs: Does Poking Both Ends Justify the Means?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2015 |
Per-rectal diclofenac decreases the risk of post-ERCP pancreatitis: What about intramuscular diclofenac?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2015 |
Assessment of Pharmacological Prophylaxis for Acute Pancreatitis Following ERCP in Patients with Choledoholithiasis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Bile Duct Diseases; Cholangiopancreatography, | 2015 |
Effect of body weight on fixed dose of diclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Acute Disease; Aged; Body Weight; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac; Femal | 2016 |
Comparative study of strategies for preventing post-ERCP pancreatitis after early precut sphincterotomy for biliary access.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, E | 2016 |
Therapy: can rectal NSAIDs prevent post-ERCP pancreatitis?
Topics: Acute Disease; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatogr | 2012 |
Prevention of post-ERCP pancreatitis: pharmacologic solution or patient selection and pancreatic stents?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrogr | 2004 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrogr | 2005 |
Pancreatitis associated with diclofenac.
Topics: Acute Disease; Adult; Diclofenac; Female; Humans; Pancreatitis | 1993 |